Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method
P Parikh, G Babu, R Singh, V Krishna, A Bhatt, I Bansal… - BMC cancer, 2023 - Springer
Background Precise prognostication is the key to optimum and effective treatment planning
for early-stage hormone receptor (HR) positive, HER2/neu negative breast cancer patients …
for early-stage hormone receptor (HR) positive, HER2/neu negative breast cancer patients …
[PDF][PDF] Real-World Evidence of the Impact of CanAssist Breast on Physician's Decision About the Use of Adjuvant Chemotherapy in Early Breast Cancer
SP Somashekhar, S Patil, R Kumar, K Prasad, DG Vijay… - Cureus, 2024 - cureus.com
Background Clinicians use prognostic biomarker/multi-gene-based tests for predicting
recurrence in hormone receptorpositive/HER2-negative (HR+/HER2−) early-stage breast …
recurrence in hormone receptorpositive/HER2-negative (HR+/HER2−) early-stage breast …
[PDF][PDF] Comparison of Recurrence Risk Prediction by the CanAssist Breast Test and the PREDICT Online Tool in Early Breast Cancer Patients
R Kumar, G Daga, P Sharma, A Lahiri, A Chakraborty… - Cureus, 2025 - cureus.com
Several methods, such as multi-marker (both gene/protein) tests and online/free tools, are
available for the prognostication of early breast cancer (EBC) patients. This article compares …
available for the prognostication of early breast cancer (EBC) patients. This article compares …
The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment
MS Eshwaraiah, A Gunda, GB Kanakasetty… - Cancer …, 2023 - Wiley Online Library
Abstract Background Assessment of Ki67 by immunohistochemistry (IHC) has limited utility
in clinical practice owing to analytical validity issues. According to International Ki67 …
in clinical practice owing to analytical validity issues. According to International Ki67 …
Digital mammogram based robust feature extraction and selection for effective breast cancer classification in earlier stage
Breast cancer poses a significant health risk for women, demanding early detection to
mitigate its mortality impact. Leveraging the power of Deep Learning (DL) in medical …
mitigate its mortality impact. Leveraging the power of Deep Learning (DL) in medical …
Risk Stratification of Early Breast Cancer (HR+/HER 2–) by CanAssist Breast and Its Corelation with Other Online Prognostic Tools: Experience from a Single Center
A Bapna, S Patni, N Patni, AK Gupta… - Indian Journal of …, 2023 - thieme-connect.com
Introduction Risk assessment by various methods for HR+/HER2–early-stage breast cancer
(EBC) patients help clinicians stratify risk and tailor individual treatment. Multiple prognostic …
(EBC) patients help clinicians stratify risk and tailor individual treatment. Multiple prognostic …